Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

6.3%

1 terminated/withdrawn out of 16 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

19%

3 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed trials have results

Key Signals

2 recruiting6 with results

Enrollment Performance

Analytics

Phase 2

8(57.1%)

Phase 1

3(21.4%)

Phase 3

2(14.3%)

Phase 4

1(7.1%)

14Total

Phase 2(8)

Phase 1(3)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT06053814Phase 1Active Not Recruiting

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Role: lead

NCT06046222Phase 2Recruiting

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Role: lead

NCT05996003Phase 2Recruiting

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Role: lead

NCT07441200Phase 2Not Yet Recruiting

Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

Role: lead

NCT07441278Phase 2Not Yet Recruiting

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Role: lead

NCT04854096Phase 2Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Role: lead

NCT04060199Phase 3Completed

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Role: lead

NCT04956289Phase 2Completed

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Role: lead

NCT04768062Phase 3Active Not Recruiting

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Role: lead

NCT03167255Phase 2Completed

Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Role: lead

NCT04687020Phase 4Active Not Recruiting

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Role: lead

NCT01423851Phase 1Completed

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Role: lead

NCT02740972Phase 2Completed

Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Role: lead

NCT04337112Unknown

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

Role: lead

NCT03680365Completed

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

Role: collaborator

NCT00094003Phase 1Completed

Study of NS-9 in Patients With Liver Metastases

Role: lead

All 16 trials loaded